Randomized Controlled Trial of the efficacy and safety of Ranibizumab and Aflibercept for polypoidal chroidal vasculopathy
Not Applicable
- Conditions
- polypoidal chroidal vasculopathy
- Registration Number
- JPRN-UMIN000010562
- Lead Sponsor
- Department of Ophthalmology, Ehime university faculty of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
PCV with type 2 CNV. severe glaucoma,diabetic macular edema,diabetic retinopath. intraocular surgery(<2 months). allergy to fluorescein or indocyanine green.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of best-collected visual acuity at month 6
- Secondary Outcome Measures
Name Time Method Change of polypoidal lesion, retinal edema,subretinal fluid,serous PED, the number of injection of medicine, side effect